November 28, 2011 at 12:04 PM EST
Regeneron/Bayer Start China Trial of Wet AMD Drug
Regeneron Pharma and Bayer have begun a China Phase III trial of Eylea™ (aflibercept) Injection, a treatment for neovascular age-related macular degeneration (wet AMD). Earlier this month, Eylea was granted FDA approval for this indication in the US. More details.... Stock Symbol: (NSDQ: REGN) (XETRA: BAY) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here
//-->